Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C26-A6: sourced facts only. name: "The objective is to evaluate the therapeutic efficacy of the combination of C26-A6 and MYCi975, small molecule inhibitors of AEG-1 and MYC, respectively, for HCC." [DOI:10.1158/1538-7445.am2025-6935]; target: "The objective is to evaluate the therapeutic efficacy of the combination of C26-A6 and MYCi975, small molecule inhibitors of AEG-1 and MYC, respectively, for HCC." [DOI:10.1158/1538-7445.am2025-6935]; developer: "Virginia Commonwealth University, Richmond, VA." [DOI:10.1158/1538-7445.am2025-6935]; modality: "The objective is to evaluate the therapeutic efficacy of the combination of C26-A6 and MYCi975, small molecule inhibitors of AEG-1 and MYC, respectively, for HCC." [DOI:10.1158/1538-7445.am2025-6935]; stage: "In all four cell lines, MYCi975 was more potent than C26-A6 to inhibit cell viability." [DOI:10.1158/1538-7445.am2025-6935]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C26-A6.